Protocol EC-FV-05: An Open-label, Multi-center, Extension Study of EC145 Administered Weeks 1 and 3 of a 4-Week Cycle in Subjects Enrolled in a Previous Study With EC145

Trial Profile

Protocol EC-FV-05: An Open-label, Multi-center, Extension Study of EC145 Administered Weeks 1 and 3 of a 4-Week Cycle in Subjects Enrolled in a Previous Study With EC145

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Jan 2016

At a glance

  • Drugs Vintafolide (Primary)
  • Indications Endometrial cancer; Non-small cell lung cancer; Ovarian cancer
  • Focus Adverse reactions
  • Sponsors Endocyte; Merck Sharp & Dohme
  • Most Recent Events

    • 19 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 05 Jun 2014 Planned End Date changed from 1 Dec 2016 to 1 Apr 2018 as reported by ClinicalTrials.gov record.
    • 05 Mar 2012 Planned end date changed from 1 May 2012 to 1 Dec 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top